secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001104659-26-052165
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q1 revenue $1.46B (-4% YoY); declares $0.02 dividend; Sun Pharma merger pending
--------------------------------------------------------------------------------

- Revenue $1.460B, down 4% as-reported, down 9% ex-FX; Women's Health -16%, Biosimilars +23%.
- GAAP diluted EPS $0.55, Adjusted diluted EPS $0.71; Adjusted EBITDA $415M (28.4% margin).
- Board declares quarterly dividend of $0.02/share, payable June 11 to holders of record May 11.
- Pending all-cash merger with Sun Pharma expected to close early 2027; guidance and earnings calls suspended.
- Net income $146M vs $87M YoY; cash and equivalents $1.12B, debt $8.57B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/0001104659-26-052165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/tm2613165d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-052165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer